Cedars-Sinai regenerative medicine investigators have received approval from the U.S. Food and Drug Administration to test a combination stem cell-gene therapy they developed to stall the progression of amyotrophic lateral sclerosis, a neurological disease that causes progressive paralysis and ultimately death.

Read the original post:
Cedars-Sinai receives FDA approval to examine safety of combination stem cell-gene therapy in ALS patients

Scroll to Top